One study highlighted how neoadjuvant anti-PD-1 immunotherapy fortifies Tumor-Infiltrating Lymphocytes (TILs), inducing a pronounced interferon response within the tumor microenvironment. This evidence concerns the gene PDCD1 and neoplasm.